Jereme M.  Sylvain net worth and biography

Jereme Sylvain Biography and Net Worth

CAO of DexCom

Jereme Sylvain is Executive Vice President and Chief Financial Officer at Dexcom.

In this role, Jereme is responsible for Dexcom’s Finance organization and Investor Relations. He previously served as Dexcom’s Senior Vice President of Finance and Chief Accounting Officer and Vice President, Finance and Corporate Controller.

Prior to Dexcom, Jereme held various positions at NuVasive, Inc., including Chief Accounting Officer, Vice President, Finance and Vice President and Corporate Controller. In these roles, he was responsible for NuVasive’s global accounting function, corporate FP&A, treasury, and shared service functions. Jereme has also held leadership roles at Thermo Fisher Scientific and was part of the public accounting firm Ernst & Young LLP.

Jereme received his Certified Public Accounting license after receiving a Bachelor of Science degree in Finance from Arizona State University and a Master of Science in Accountancy from the University of Notre Dame.

What is Jereme M. Sylvain's net worth?

The estimated net worth of Jereme M. Sylvain is at least $6.80 million as of June 10th, 2024. Mr. Sylvain owns 84,948 shares of DexCom stock worth more than $6,799,238 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Sylvain may own. Additionally, Mr. Sylvain receives an annual salary of $1,130,000.00 as CAO at DexCom. Learn More about Jereme M. Sylvain's net worth.

How old is Jereme M. Sylvain?

Mr. Sylvain is currently 44 years old. There are 6 older executives and no younger executives at DexCom. The oldest executive at DexCom is Mr. Kevin Ronald Sayer, Executive Chairman, CEO & President, who is 66 years old. Learn More on Jereme M. Sylvain's age.

What is Jereme M. Sylvain's salary?

As the CAO of DexCom, Inc., Mr. Sylvain earns $1,130,000.00 per year. There are 4 executives that earn more than Mr. Sylvain. The highest earning executive at DexCom is Mr. Kevin Ronald Sayer, Executive Chairman, CEO & President, who commands a salary of $3,230,000.00 per year. Learn More on Jereme M. Sylvain's salary.

How do I contact Jereme M. Sylvain?

The corporate mailing address for Mr. Sylvain and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Jereme M. Sylvain's contact information.

Has Jereme M. Sylvain been buying or selling shares of DexCom?

Jereme M. Sylvain has not been actively trading shares of DexCom in the last ninety days. Learn More on Jereme M. Sylvain's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 24 times. They sold a total of 248,077 shares worth more than $32,452,099.04. The most recent insider tranaction occured on November, 20th when EVP Sadie Stern sold 4,259 shares worth more than $318,275.07. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 11/20/2024.

Jereme M. Sylvain Insider Trading History at DexCom

See Full Table

Jereme M. Sylvain Buying and Selling Activity at DexCom

This chart shows Jereme M. Sylvain's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $80.04
Low: $75.47
High: $81.51

50 Day Range

MA: $74.53
Low: $67.10
High: $81.01

2 Week Range

Now: $80.04
Low: $62.34
High: $142.00

Volume

11,494,120 shs

Average Volume

3,910,878 shs

Market Capitalization

$31.26 billion

P/E Ratio

47.93

Dividend Yield

N/A

Beta

1.12